An interventional study of Advanced Platelet-Rich Fibrin and Sodium hyaluronate in Third Molar Surgery, sponsored by Inonu University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 19 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Inonu University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled clinical trial evaluated the effects of advanced platelet-rich fibrin (A-PRF) and hyaluronic acid (HA) on healing after surgical removal of impacted mandibular third molars. Participants were assigned to one of three groups: A-PRF applied to the extraction socket, HA applied to the extraction socket, or a control group receiving no additional biomaterial. Postoperative pain, facial swelling, and maximum mouth opening were assessed during the first postoperative week. Radiographic bone healing was evaluated using fractal dimension and mean gray value measurements on panoramic radiographs obtained on postoperative days 7 and 90. The study aimed to determine whether A-PRF or HA could improve postoperative clinical recovery and radiographic bone healing compared with standard treatment alone.
Inonu University is the lead sponsor of 398 studies on the registry; 97 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients aged 19-29 years. (ASA) physical status I. Presence of an impacted mandibular third molar indicated for surgical removal. Ability and willingness to comply with the study procedures and follow-up visits.
Provision of written .
Exclusion Criteria:
Smoking. Poor oral hygiene. Presence of acute infection in the surgical area. Presence of a cystic or tumoral lesion associated with the impacted tooth. Uncontrolled periodontal disease. Refusal to participate or withdrawal of consent. Use of analgesics or antibiotics within 12 hours before surgery. Surgical procedure lasting longer than 40 minutes.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Advanced platelet-rich fibrin (A-PRF) was applied to the extraction socket following surgical removal of the impacted mandibular third molar.
Biological: Advanced Platelet-Rich Fibrin
One milliliter of 0.8% sodium hyaluronate gel was applied to the extraction socket following surgical removal of the impacted mandibular third molar.
Drug: Sodium hyaluronate
No additional biomaterial was applied to the extraction socket following surgical removal of the impacted mandibular third molar. Participants received the same surgical procedure and standard postoperative care as the other groups.
Advanced platelet-rich fibrin (A-PRF) was prepared from autologous venous blood by centrifugation at 1500 rpm for 14 minutes. The resulting A-PRF membrane was placed into the extraction socket immediately after surgical removal of the impacted mandibular third molar.
One milliliter of 0.8% sodium hyaluronate gel was applied directly into the extraction socket immediately after surgical removal of the impacted mandibular third molar.
Fractal Dimension of the Extraction Socket
Fractal dimension (FD) was used to evaluate the trabecular bone pattern within the extraction socket on digital panoramic radiographs. A standardized 32 × 32-pixel region of interest was selected at the center of the extraction socket, and FD was calculated using the box-counting method in ImageJ.
Time frame: Postoperative days 7 and 90
Mean Radiographic Gray Value
Mean radiographic gray value was measured within a standardized 32 × 32-pixel region of interest located at the center of the extraction socket on digital panoramic radiographs using ImageJ software.
Time frame: Postoperative days 7 and 90
Postoperative Pain
Postoperative pain intensity was assessed using a visual analog scale (VAS).
Time frame: Postoperative days 1, 3, and 7
Postoperative Facial Swelling
Facial swelling was assessed using standardized facial measurements obtained between predefined anatomical landmarks before surgery and during postoperative follow-up.
Time frame: Baseline and postoperative days 1, 3, and 7
Maximum Mouth Opening
Maximum mouth opening was measured in millimeters as the maximum interincisal distance.
Time frame: Baseline and postoperative days 1, 3, and 7
Plan to share: Yes — De-identified individual participant data underlying the results reported in the published article will be shared. These data will include demographic characteristics, group allocation, postoperative pain scores, facial swelling measurements, maximum mouth opening measurements, fractal dimension values, and mean radiographic gray values.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: The study will be prepared for publication as a manuscript within six months.
Access criteria: All individual participant data (IPD) and supporting information will be available after publication of the article.
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Jun 2026, 10 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronic Acid